- Home
- TLSA vs OKUR Comparison
TLSA vs OKUR Comparison
Compare TLSA & OKUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- OKUR
- Stock Information
- Founded
- TLSA 2013
- OKUR 2011
- Country
- TLSA United Kingdom
- OKUR United States
- Employees
- TLSA N/A
- OKUR N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- OKUR
- Sector
- TLSA Health Care
- OKUR
- Exchange
- TLSA Nasdaq
- OKUR NYSE
- Market Cap
- TLSA 87.8M
- OKUR 77.2M
- IPO Year
- TLSA 2000
- OKUR N/A
- Fundamental
- Price
- TLSA $0.74
- OKUR $5.79
- Analyst Decision
- TLSA
- OKUR Strong Buy
- Analyst Count
- TLSA 0
- OKUR 3
- Target Price
- TLSA N/A
- OKUR $36.00
- AVG Volume (30 Days)
- TLSA 442.0K
- OKUR 176.8K
- Earning Date
- TLSA 01-28-2025
- OKUR 02-14-2025
- Dividend Yield
- TLSA N/A
- OKUR N/A
- EPS Growth
- TLSA N/A
- OKUR N/A
- EPS
- TLSA N/A
- OKUR N/A
- Revenue
- TLSA N/A
- OKUR N/A
- Revenue This Year
- TLSA N/A
- OKUR N/A
- Revenue Next Year
- TLSA N/A
- OKUR N/A
- P/E Ratio
- TLSA N/A
- OKUR N/A
- Revenue Growth
- TLSA N/A
- OKUR N/A
- 52 Week Low
- TLSA $0.41
- OKUR $5.75
- 52 Week High
- TLSA $1.74
- OKUR $20.00
- Technical
- Relative Strength Index (RSI)
- TLSA 44.91
- OKUR N/A
- Support Level
- TLSA $0.68
- OKUR N/A
- Resistance Level
- TLSA $0.80
- OKUR N/A
- Average True Range (ATR)
- TLSA 0.08
- OKUR 0.00
- MACD
- TLSA 0.01
- OKUR 0.00
- Stochastic Oscillator
- TLSA 34.34
- OKUR 0.00
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About OKUR ONKURE THERAPEUTICS INC
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.